Genus PLC ADR GENSY
Trading Information
- Previous Close Price
- $31.25
- Day Range
- $28.38–28.38
- 52-Week Range
- $28.38–44.14
- Bid/Ask
- $0.01 / $19,229.27
- Shares Outstanding
- 64.31M
- Market Cap
- $1.88B
- Volume/Avg
- 3,345 / 3,244
Key Statistics
- Price/Earnings (Normalized)
- 19.79
- Price/Sales
- 2.16
- Dividend Yield (Trailing)
- 1.54%
- Dividend Yield (Forward)
- 1.54%
- Dividend Payment Schedule
- Apr, Dec
- Total Yield
- 1.54%
Company Profile
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The company's operating segments are: Genus PIC, which derives the maximum revenue and includes the porcine sales business; Genus ABS, the bovine sales business; and Genus Research and Development. Geographically, it generates the maximum revenue from North America, and the rest from Latin America, Europe, Asia, and other regions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3,045
- Website
- https://www.genusplc.com
Valuation
Metric | GENSY |
|---|---|
Price/Earnings (Normalized) | 19.79 |
Price/Book Value | 1.85 |
Price/Sales | 2.16 |
Price/Cash Flow | 16.66 |
Price/Earnings
GENSY
Financial Strength
Metric | GENSY |
|---|---|
Quick Ratio | 1.42 |
Current Ratio | 2.22 |
Interest Coverage | 20.65 |
Quick Ratio
GENSY
Profitability
Metric | GENSY |
|---|---|
Return on Assets (Normalized) | 7.70% |
Return on Equity (Normalized) | 12.52% |
Return on Invested Capital (Normalized) | 10.95% |
Return on Assets
GENSY
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|z$&#h<^ | LOCK|cW?!W | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|&KH>k?< | LOCK|H!?V | $95B | |||
| Moderna Inc MRNA | LOCK|#Y&RgS | LOCK|<w? | $79B | |||
| argenx SE ADR ARGX | LOCK|#T>bxx | LOCK|@pd | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?BGm?f | LOCK|Zw? | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Z%#>&WW | LOCK|<LV< | $30B | |||
| Incyte Corp INCY | LOCK|$PZ>TNf | LOCK|hm | $23B | |||
| BioNTech SE ADR BNTX | LOCK|X!?@%D | LOCK|mzy | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|w#t&@Tp | LOCK|#Y<M | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|!f$kwcF | LOCK|NJ | $15B |